Clinical Trials
6 trialsNCT04305054 2026-05-28
KEYMAKER-U02
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT03058289 2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2 Completed
NCT03852251 2024-08-02
A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma
Akeso
Phase 1/2 Completed
NCT02735239 2024-03-22
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT03639714 2023-09-13
A Study of a Personalized Neoantigen Cancer Vaccine
Gritstone bio, Inc.
Phase 1/2 Completed
NCT03953235 2023-09-13
A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens
Gritstone bio, Inc.
Phase 1/2 Completed